The Carlat Psychiatry Podcast
MDMA: What Went Wrong Part 1
Jun 10, 2024
Chris Aiken, MD, a psychiatrist specializing in psychedelic therapy, discusses the FDA panel's rejection of MDMA-assisted psychotherapy and the challenges in accessing such therapy in the United States. The podcast explores contrasting experiences in MDMA therapy, origins of MDMA in therapy, the role of therapists in maintaining boundaries, and the positive effects of MDMA on PTSD symptoms.
20:01
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Ethical concerns surfaced in MDMA therapy due to boundary violations and sexual misconduct during clinical trials.
- Despite MDMA's potential in treating PTSD, its reclassification as ecstasy underscores ethical and safety dilemmas.
Deep dives
MDMA-Assisted Therapy for PTSD: A Cautionary Tale
The rejection of MDMA-assisted psychotherapy for PTSD by an FDA panel has stirred discussions. A decade-old video featuring a woman's breakthrough under MDMA effects contrasts with a disturbing 2014 incident during a MAPS clinical trial session. This incident involved alleged boundary violations and sexual misconduct by therapists, shedding light on ethical concerns within psychedelic therapy practices.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
